Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production

Date
2021-08-04
Authors
Mallapragada, Surya
Senapati, Sujata
Darling, Ross
Ross, Kathleen
Wannemeuhler, Michael
Narasimhan, Balaji
Mallapragada, Surya
Narasimhan, Balaji
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Research Projects
Organizational Units
Ames Laboratory
Organizational Unit
Neuroscience
Organizational Unit
Journal Issue
Series
Department
Ames LaboratoryNeuroscienceMaterials Science and EngineeringVeterinary Microbiology and Preventive MedicineChemical and Biological EngineeringVeterinary Microbiology and Preventive Medicine
Abstract

Host antibody responses are pivotal for providing protection against infectious agents. We have pioneered a new class of self-assembling micelles based on pentablock copolymers that enhance antibody responses while providing a low inflammatory environment compared to traditional adjuvants. This type of “just-right” immune response is critical in the rational design of vaccines for older adults. Here, we report on the mechanism of enhancement of antibody responses by pentablock copolymer micelles, which act as scaffolds for antigen presentation to B cells and cross-link B cell receptors, unlike other micelle-forming synthetic block copolymers. We exploited this unique mechanism and developed these scaffolds as a platform technology to produce antibodies in vitro. We show that this novel approach can be used to generate laboratory-scale quantities of therapeutic antibodies against multiple antigens, including those associated with SARS-CoV-2 and Yersinia pestis, further expanding the value of these nanomaterials to rapidly develop countermeasures against infectious diseases.

Comments

This article is published as Senapati, Sujata, Ross J. Darling, Kathleen A. Ross, Michael J. Wannemeuhler, Balaji Narasimhan, and Surya K. Mallapragada. "Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production." Science Advances 7, no. 32 (2021): eabj1691. DOI: 10.1126/sciadv.abj1691. Posted with permission.

Description
Keywords
Citation
DOI
Collections